Preference for vigorous exercise versus sedentary sucrose drinking: an animal model of anergia induced by dopamine receptor antagonism.

Behavioural Pharmacology
Mercè CorreaJohn D Salamone

Abstract

Motivation has activational and directional components. Mesolimbic dopamine is critical for the regulation of behavioral activation and effort-related processes in motivated behaviors. Impairing mesolimbic dopamine function leads to fatigue and anergia, but leaves intact other aspects of reinforce seeking behaviors, such as the consummatory or hedonic component. In male Swiss mice, we characterized the impact of dopamine antagonism on the selection of concurrently presented stimuli that have different vigor requirements. We analyzed running wheel activity versus sucrose solution intake, typically used as a measure of anhedonia. Results are compared with data from nonconcurrent presentation to those stimuli. In the concurrent presentation experiment, control mice preferred to spend time running compared to sucrose intake. Dopamine antagonism shifted relative reinforcer preference, reducing time spent on the running wheel, but actually increasing time-consuming sucrose. Mice increased frequency of bouts for both reinforcers, suggesting that there was fatigue in the running wheel rather than aversion. Moreover, satiation or habituation by preexposing animals to both reinforcers did not shift preferences. In the nonconcurrent exper...Continue Reading

References

Nov 1, 1990·Pharmacology, Biochemistry, and Behavior·D Treit, K C Berridge
Aug 1, 1968·Journal of Comparative and Physiological Psychology·A Routtenberg
Aug 1, 1995·Pharmacology, Biochemistry, and Behavior·R B KanarekJ Przypek
Feb 13, 2001·Neuroscience and Biobehavioral Reviews·J E SteinerK C Berridge
Aug 2, 2002·Pharmacology, Biochemistry, and Behavior·Kelly P CosgroveMarilyn E Carroll
Nov 26, 2002·Behavioural Brain Research·Mercè CorreaJohn D Salamone
Jun 28, 2003·Nutrition Reviews·Takashi Yamamoto
Oct 3, 2003·The American Journal of Clinical Nutrition·Allen S LevineBlake A Gosnell
Jul 6, 2004·Physiology & Behavior·Claire Matson Cannon, Mustafa R Bseikri
Jun 18, 2005·Behavioural Pharmacology·T W BelkeJ A Beye
Dec 2, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Barbara CagniardXiaoxi Zhuang
Nov 1, 1969·Journal of the Experimental Analysis of Behavior·W M Baum, H C Rachlin
Sep 1, 1986·Journal of the Experimental Analysis of Behavior·W D PierceD P Boer
Jul 1, 2006·Journal of the Experimental Analysis of Behavior·T Belke, M Dunbar
Sep 16, 2006·Psychopharmacology·T W Robbins, B J Everitt
Oct 13, 2006·Psychopharmacology·M Flavia Barbano, Martine Cador
Nov 27, 2008·Cognitive, Affective & Behavioral Neuroscience·Stan B FlorescoCatharine A Winstanley
Oct 15, 2009·Frontiers in Behavioral Neuroscience·John D SalamoneMarta Pardo
Nov 20, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Doron TodderBernhard T Baune
Nov 13, 2012·Neuron·John D Salamone, Mercè Correa
Dec 7, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Eric J NunesJohn D Salamone
Sep 2, 2015·Current Topics in Behavioral Neurosciences·John D SalamoneMercè Correa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here